Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Leqembi dominates the Alzheimer's market with seamless logistical rollout, accelerating revenue and EPS growth back to high single digits.
Leqembi Market Rejection: Severe administration bottlenecks and ARIA safety concerns permanently stunt Leqembi uptake.
Biogen is a mature biotechnology firm navigating a profound portfolio transition. Legacy multiple sclerosis products (Tecfidera, etc.) are facing severe generic competition, placing the burden of future growth on recent pipeline launches, particularly in Alzheimer's (Leqembi) and rare diseases. The company trades at a notable discount to pharmaceutical peers (12x forward P/E), reflecting these transitional risks and the uncertain trajectory of its neuroscience pipeline.
Biogen is a mature biotechnology firm navigating a profound portfolio transition. Legacy multiple sclerosis products (Tecfidera, etc.) are facing severe generic competition, placing the burden of future growth on recent pipeline launches, particularly in Alzheimer's (Leqembi) and rare diseases. The company trades at a notable discount to pharmaceutical peers (12x forward P/E), reflecting these transitional risks and the uncertain trajectory of its neuroscience pipeline.
Legacy MS franchise cash flows
Alzheimer's first-mover pipeline (Leqembi)
Alzheimer's therapeutic breakthrough scaling.
Buy rating driven by intrinsic cash flow models capturing legacy MS cash flows, overriding sentiment-driven pessimistic street internal valuation cross-checks ($217.03).
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Leqembi adoption is stunted by administration bottlenecks or safety concerns while the MS franchise erodes faster than modeled, forcing sustained margin compression and multiple degradation.
Legacy MS franchise cash flows
Alzheimer's first-mover pipeline (Leqembi)
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $2.1B after capex $197.8M, with terminal value at 62.0% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If Leqembi guidance is raised -> Buy. If MS erosion accelerates -> Hold/Sell.
If Leqembi guidance is raised -> Buy. If MS erosion accelerates -> Hold/Sell.
If Leqembi guidance is raised -> Buy. If MS erosion accelerates -> Hold/Sell.
If Leqembi guidance is raised -> Buy. If MS erosion accelerates -> Hold/Sell.
Transition from high-margin legacy cash cow to heavy reinvestment in new product commercialization.
Alzheimer's therapeutic breakthrough scaling.
Generic substitution and patent cliff.
Transition from high-margin legacy cash cow to heavy reinvestment in new product commercialization.
Standard weight given binary pipeline risk vs solid cash floor.
Trim near $300 or exit if Leqembi rollout stalls.
Strong Buy. The $253.08 mid fair value highlights market mispricing of legacy cash flows versus pipeline execution risk.
Contrarian value play against peak street pessimism.
Buy. The $253.08 mid fair value highlights market mispricing of legacy cash flows versus pipeline execution risk.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Leqembi adoption stalls due to safety concerns and logistical bottlenecks while legacy MS products collapse rapidly.
Severe administration bottlenecks and ARIA safety concerns permanently stunt Leqembi uptake.
Legacy MS products lose market share far faster than expected, crashing trailing cash flows before pipeline kicks in.
Global structural drug pricing pressures disproportionately target Biogen's high-margin neurology portfolio.
The five developments that would weaken our investment case.
Failure of new franchise growth to offset legacy declines leaves overall top-line expansion negative. Stunted commercial uptake impairs the multi-year revenue replacement cycle, depressing cash generation and triggering valuation multiple derating across therapeutic pipelines.
Current:2.2% for the period ended 2025-12-31
Alert if< 0.0% year-over-year over any fiscal year
Severe pricing pressures or higher product cost burdens compress profit spreads across the neurology portfolio. Substantial margin contraction impairs operating cash flows needed to support continuous clinical pipeline development and corporate debt service obligations.
Current:75.7% for the period ended 2025-12-31
Alert if< 70.0% over any fiscal year
Elevated capital requirements or heavier operational expenditures diminish the conversion of sales into free cash flow. Higher structural reinvestment burdens restrict capital flexibility, limiting capacity for strategic business development and lowering overall return on invested capital.
Current:Operating margin was 25.0% for the period ended 2025-12-31
Alert if> 2.0% of revenue over any fiscal year
Losing commercial leadership in the core growth franchise permanently truncates the expected multi-year revenue ramp. Diminished market share caps long-term cash flow generation and prevents the therapeutic franchise from compensating for continuing legacy portfolio attrition.
Current:Leading early-mover market position as of the 2026-05-13 analysis date
Alert ifLoss of lead market share in Alzheimer's disease with product market share falling to < 50.0% over any fiscal year
Rapid erosion of high-margin multiple sclerosis revenues before replacement therapies mature diminishes profitability and return metrics. Crashing legacy cash flows tightens balance sheet constraints, threatening research funding and accelerating multiple degradation across the business.
Current:5.8% as of the 2026-05-13 analysis date
Alert if< 4.0% over any trailing twelve-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
Leqembi dominates the Alzheimer's market with seamless logistical rollout, accelerating revenue and EPS growth back to high single digits.
Leqembi scales moderately, offsetting the decline of the legacy MS franchise, allowing baseline EPS growth.
Warning level: < 0.0% year-over-year over any fiscal year. Failure of new franchise growth to offset legacy declines leaves overall top-line expansion negative. Stunted commercial uptake impairs the multi-year revenue replacement cycle, depressing cash generation and triggering valuation multiple derating across therapeutic pipelines.
Warning level: < 70.0% over any fiscal year. Severe pricing pressures or higher product cost burdens compress profit spreads across the neurology portfolio. Substantial margin contraction impairs operating cash flows needed to support continuous clinical pipeline development and corporate debt service obligations.
Warning level: > 2.0% of revenue over any fiscal year. Elevated capital requirements or heavier operational expenditures diminish the conversion of sales into free cash flow. Higher structural reinvestment burdens restrict capital flexibility, limiting capacity for strategic business development and lowering overall return on invested capital.
Warning level: Loss of lead market share in Alzheimer's disease with product market share falling to < 50.0% over any fiscal year. Losing commercial leadership in the core growth franchise permanently truncates the expected multi-year revenue ramp. Diminished market share caps long-term cash flow generation and prevents the therapeutic franchise from compensating for continuing legacy portfolio attrition.
Warning level: < 4.0% over any trailing twelve-month period. Rapid erosion of high-margin multiple sclerosis revenues before replacement therapies mature diminishes profitability and return metrics. Crashing legacy cash flows tightens balance sheet constraints, threatening research funding and accelerating multiple degradation across the business.
| $9.84B |
| $9.68B |
| $9.89B |
| -0.9% |
| Gross profit | $7.90B | $7.30B | $7.37B | $7.49B | -1.8% |
| Operating income | $3.84B | $1.54B | $2.16B | $1.82B | -22.0% |
| Net income | $3.05B | $1.16B | $1.63B | $1.29B | -24.9% |
| EPS (diluted) | $20.87 | $7.97 | $11.18 | $8.79 | -25.0% |
| EBITDA | $4.36B | $2.04B | $2.83B | $2.60B | -15.8% |
| R&D | $2.23B | $2.45B | $1.98B | $1.78B | -7.3% |
| SG&A | $2.40B | $2.55B | $2.40B | $2.43B | +0.4% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 9,890,600,000 |
|---|---|
| Cost of revenue | 2,404,200,000 |
| Gross profit | 7,486,400,000 |
| Operating expenses | 5,017,400,000 |
| Operating income | 2,469,000,000 |
| Non-operating items and tax | -1,176,100,000 |
| Net income | 1,292,900,000 |
| Total assets | 29,439,500,000 |
|---|---|
| Cash | 3,008,500,000 |
| Current assets | 8,974,100,000 |
| Total liabilities | 11,182,700,000 |
| Current liabilities | 3,349,400,000 |
| Shareholders’ equity | 18,256,800,000 |
Point-in-time financial data used in the 2026-05-13 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | — | — | — | — | — | — | — | — | 1.8B | — | — | — | — | — | — | — | — | — | — | — | — |
| 2022-12-31 | 10.2B | 4.4B | 3B | 1.4B | 1.1B | 243.2M | 518.4M | 254.1M | 750M | — | -1B | — | — | — | — | 3.4B | 6.6B | 28.5% | — | 6.2% | — |
| 2023-12-31 | 9.8B | 2B | 1.2B | 1.5B | 1.2B | 311.4M | 494.8M | 264.2M | 0 | — | 187.3M | — | — | — | — | 1B | 7.3B | 18.8% | — | 5.9% | — |
| 2024-12-31 | 9.7B | 2.8B | 1.6B | 2.9B | 2.5B | 359.8M | 673.2M | 291.2M | 0 | — | -650M | — | — | — | — | 2.4B | 6.6B | 23.6% | — | 6.2% | — |
| 2025-12-31 | 9.9B | 2.6B | 1.3B | 2.2B | 2B | 235.4M | 779.9M | 290.8M | — | — | -16.9M | — | — | — | — | 3B | 6.6B | 25.0% | — | 6.7% | — |
BIIB trades at 12.0x forward earnings against a peer median of 14.3x; EV/EBITDA of 9.0x against a peer median of 14.1x; 6 peers.
| Level | Action |
|---|
| Thesis break | Trim near $300 or exit if Leqembi rollout stalls. |
| Johnson & Johnson |
| 17.6x |
| 5.6x |
| 16.7x |
| 26.4% |
| 27.4% |
| ABBV | AbbVie Inc. | 12.8x | 5.8x | 14.1x | 62.2% | 32.2% |
| MRK | Merck & Co. Inc. | 11.7x | 4.2x | 10.9x | 18.9% | 38.6% |
| AMGN | Amgen Inc. | 14.3x | 4.9x | 13.4x | 101.3% | 33.8% |
